1753253|t|Galanthamine treatment in Alzheimer's disease.
1753253|a|18 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.
1753253	0	12	Galanthamine	Chemical	MESH:D005702
1753253	26	45	Alzheimer's disease	Disease	MESH:D000544
1753253	50	58	patients	Species	9606
1753253	117	119	AD	Disease	MESH:D000544
1753253	181	195	cholinesterase	Gene	590
1753253	206	218	Galanthamine	Chemical	MESH:D005702
1753253	423	431	patients	Species	9606
1753253	Negative_Correlation	MESH:D005702	590
1753253	Negative_Correlation	MESH:D005702	MESH:D000544

